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Background: Adjuvant chemotherapy is a standard treatment option for patients with stage III 
and high-risk stage II colon cancer. Sex is one of several factors responsible for the wide inter-
patient variability in drug responses. Amalgamated data on the effect of sex on the toxicity of 
current standard adjuvant treatment for colorectal cancer are missing.  
Methods: Objective of our study was to compare incidence and severity of major toxicities of 
fluoropyrimidine- (5-FU or capecitabine) based adjuvant chemotherapy, with or without 
oxaliplatin, between male and female patients after curative surgery for colon cancer. Adult 
patients enrolled in 27 relevant randomized trials included in the ACCENT database, a large, 
multi-group, international data repository containing individual patient data, were included. 
Comparisons were conducted using logistic regression models (stratified by study and 
treatment arm) within each type of adjuvant chemotherapy (5FU, FOLFOX, Capecitabine, 
CAPOX, and FOLFIRI). The following major toxicities were compared (grade III/IV and grade I-IV, 
according to NCI-CTC criteria, regardless of attribution): nausea, vomiting, nausea/vomiting, 
stomatitis, diarrhea, leukopenia, neutropenia, thrombocytopenia, anemia, and neuropathy (in 
patients treated with oxaliplatin).  
Results: Data from 34,640 patients were analyzed. Statistically significant and clinically relevant 
differences in the occurrence of grade III/IV non-hematological (especially nausea [5FU: Odds 
Ratio (OR) = 2.33, 95% Confidence Interval (CI) = 1.90 to 2.87, p-value <.001, FOLFOX: OR =2.34, 
95% CI =1.76 to 3.11, p-value <.001], vomiting [5FU: OR =2.38, 95% CI =1.86 to 3.04, p-value 
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to 3.46, p-value <.001], and diarrhea [5FU: OR =1.35, 95% CI =1.21 to 1.51, p-value <.001, 
FOLFOX: OR =1.60, 95% CI =1.35 to 1.90, p-value <.001, FOLFIRI: OR= 1.57, 95% CI =1.25 to 1.97, 
p-value <.001]), as well as hematological toxicities (neutropenia [5FU: OR =1.55, 95% CI =1.37 to 
1.76, p-value <.001, FOLFOX: OR =1.96, 95% CI =1.71 to 2.25, p-value <.001, FOLFIRI: OR =2.01, 
95% CI =1.66 to 2.43, p-value <.001, Capecitabine: OR =4.07, 95% CI =1.84 to 8.99, p-value 
<.001] and leukopenia [5FU: OR =1.74, 95% CI =1.40 to 2.17, p-value <.001, FOLFIRI: OR =1.75, 
95% CI =1.28 to 2.40, p-value <.001]), were observed, with women being consistently at 
increased risk.  
Conclusions: Our analysis confirms that women with colon cancer receiving adjuvant 
fluoropyrimidine-based chemotherapy are at increased risk of toxicity. Given the known sex 
differences in fluoropyrimidine pharmacokinetics, sex-specific dosing of fluoropyrimidines 
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An individuals’ sex is one of the most important modulators of disease risk and response 
to treatment [1]. The importance and potential for sex and gender analyses to foster scientific 
discovery has been highlighted recently [2]. A growing number of peer-reviewed journals now 
require sex- or gender-specific reporting [3, 4]. In fact, the Journal of the National Cancer 
Institute was the first journal to include instructions for addressing the effects of sex as part of 
its manuscript preparation policy [5].  Although ESMO recently addressed the topic [6], 
oncology lags behind other disciplines, such as cardiology. A PubMed search for “sex”, 
“toxicity”, and “chemotherapy”, conducted in 2016 before initiating this analysis, including all 
solid tumors, identified 11 studies including more than 100 participants. Available studies in 
patients with colorectal cancer did not include prospective data on currently used oxaliplatin- 
or capecitabine-based regimens.  
Adjuvant chemotherapy is standard for patients with stage III and high-risk stage II colon 
cancer. The impact of a patient’s sex on the incidence and severity of adverse events has not, 
however, been well documented. Of note, while self-reported gender is that what is being 
reported, given the low frequency of transgender persons (0.3-0.5%) [7], we can assume 
biological sex and gender to be identical in 99.5 and 99.7% of patients. Therefore, as we 
consider biological differences between men and women as primarily responsible for potential 
differences in treatment effects, throughout this manuscript, we will use the term sex 
differences, and refer to males and females.  
This study aimed to compare between the sexes the incidence and severity of major 
adverse events of clinically relevant fluoropyrimidine (5-FU or capecitabine)-based adjuvant 
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This is a secondary analysis of previously conducted trials and was approved by Mayo 
Clinic Institutional Review Board. Patients provided informed consent for participating in the 
original trials, which were obtained by local enrolling centers. 
All adult patients with colorectal cancer who participated in any of the 27 relevant 
randomized clinical trials of adjuvant chemotherapy that comprise the ACCENT database were 
included. A list of all trials and treatment arms included in this analysis is provided as 
supplementary material (supplementary table 1). ACCENT (Adjuvant Colon Cancer End Points) 
[8, 9] is a large, multi-group, international data repository containing individual patient level 
information from clinical trials. Categories of chemotherapy regimens were 5-FU single-agent 
(plus folinic acid), with or without oxaliplatin (e.g., FOLFOX, FLOX),  Capecitabine as a single-
agent or in combination with oxaliplatin (CAPOX) and 5-FU (plus folinic acid) plus irinotecan 
(FOLFIRI and other regimens).  
Although FOLFIRI is not a standard adjuvant treatment, but given its frequent use in 
patients with metastatic disease, trials including this chemotherapy combination were also 
analyzed. Patients assigned to combinations of chemotherapy plus targeted treatments no 
longer used as adjuvant treatment, such as FOLFOX plus bevacizumab, FOLFOX plus cetuximab, 
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We analyzed patient characteristics and adverse events separately for each regimen 
category. Chi-square test was used to detect differences in baseline characteristics between 
male and female patients. The following major adverse events were compared (grade III/IV and 
grade I-IV, according to NCI-criteria, regardless of attribution) between males and females: 
nausea, vomiting, nausea/vomiting, stomatitis, diarrhea, leukopenia, neutropenia, 
thrombocytopenia, anemia, and neuropathy, in patients treated with oxaliplatin. Results for 
comparisons between grade I-IV adverse events are included in the supplementary materials. 
Total patients included in logistic models for each AE differed due to data availability including 
specific AE data missing per patient and specific AE data missing per study. In order to assess 
the association between AEs and sex, odds ratios were calculated using multivariate logistic 
models adjusting for age, grade, stage, performance score (PS), and body mass index (BMI) and 
compared using stratified Wald test. The interaction effects between sex and adjusting 
variables were tested using stratified Wald test and none of them were found to be statistically 
significant. In order to account for study and treatment-specific differences, logistic models 
were stratified by study and treatment arm. Two-sided p-values are reported. We designated 




This analysis included 34,640 patients with a median age for both males and females of 
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displayed in Table 1 according to chemotherapy regimen. Across chemotherapy regimens, we 
noted statistically significant differences in patients’ characteristics between the sexes.  
Specifically, females had more often a BMI of <18.5 (4.5% females versus 1.2% males) or 18.5-
25 kg/m2 (46.3% females versus 39.4% males), whereas males more often had a BMI of ≥25 
kg/m2 (59.3% males versus 49.2% females); females were more often under 50 years old (18.9% 
females versus 16.8% males), whereas males more often were ≥65 years old (37.5% males 
versus 36.3% females); and females more often had a performance score of 1 (20.8% females 
versus 18.6% males), whereas males more often had a performance score of 0 (80.5% males 
versus 78.5% females). 
While the differences in BMI are clearly considered as clinically meaningful, differences 
in age groups and PS are less important. Overall, 17 treatment-related deaths were observed, 
12 females and five males (Chi-square p-value=.04. Due to the rarity of these events, we 
excluded them from the logistic models, which were limited to grade I-IV and grade III/IV 
adverse events. The adjusted associations between grade III/IV hematologic AEs and sex 
according to treatment regimen are displayed in Figure 1.  While the odds of experiencing 
grade III/IV thrombocytopenia and anemia were comparable, female patients had higher odds 
of experiencing grade III/IV neutropenia (5FU: OR 1.55, 95% CI 1.37-1.76, p-value <.001, 
FOLFOX: OR 1.96, 95% CI 1.71-2.25, p-value <.001, FOLFIRI: OR 2.01, 95% CI 1.66-2.43, p-value 
<.001, Capecitabine: OR 4.07, 95% CI 1.84-8.99, p-value <.001)  and leukopenia (5FU: OR 1.74, 
95% CI 1.40-2.17, p-value <.001, FOLFIRI: OR 1.75, 95% CI 1.28-2.40, p-value <.001) which 
reached statistical significance within at least one treatment subgroup. The adjusted 
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female patients had higher odds of experiencing grade III/IV nausea (5FU: OR 2.33, 95% CI 1.90-
2.87, p-value <.001, FOLFOX: OR 2.34, 95% CI 1.76-3.11, p-value <.001), vomiting (5FU: OR 2.38, 
95% CI 1.86-3.04, p-value <.001, FOLFOX: OR 2.00, 95% CI 1.50-2.66, p-value <.001, CAPOX: OR 
2.32, 95% CI 1.55-3.46, p-value <.001), stomatitis (5FU: OR 2.20, 95% CI 1.82-2.66, p-value 
<.001), diarrhea (5FU: OR 1.35, 95% CI 1.21-1.51, p-value <.001, FOLFOX: OR 1.60, 95% CI 1.35-
1.90, p-value <.001, FOLFIRI: OR 1.57, 95% CI 1.25-1.97, p-value <.001), peripheral neuropathy 
(FOLFOX: OR 1.34, 95% CI 1.15-1.57, p-value <.001), and transaminitis (FOLFOX: OR 2.45, 95% CI 
151-3.96, p-value <.001) which reached statistical significance within at least one treatment 
subgroup, while the odds of experiencing grade III/IV peripheral neuropathy (only CAPOX 
subgroup), rash, handfoot syndrome, and transaminitis (with the exception of FOLFOX 
subgroup) were comparable. Adjusted associations between grade I-IV hematological and non-




Including 34,640 patients, our analysis is the largest to date to address in a systematic 
manner the impact of a patients’ sex on the toxicity of all currently used adjuvant 
chemotherapy regimens. Importantly, for the first time we report prospectively collected data 
on oxaliplatin-based and capecitabine-based regimens. We confirm that female patients with 
colon cancer consistently experience clinically and statistically significant greater toxicity. This 
effect is seen across regimens and most adverse events, but is greatest for severe neutropenia 
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Variability in outcomes in either efficacy or toxicity can broadly be broken down into 
two categories. Pharmacokinetic variability reflects differences within populations with respect 
to the extent of drug exposure due, for example to differences in absorption or metabolism. By 
contrast, pharmacodynamic variability is the result of differences in the biological effects of a 
drug between patients with the same drug exposure. A patient’s sex is known to affect both the 
pharmacokinetics of drug disposition and the pharmacodynamics of drug sensitivity [10] but is 
usually not taken into account for dosage individualization. In addition, current chemotherapy 
dosing according to body surface area neither takes into account the sex differences in fat-free 
body-mass [6], nor the large individual differences in body composition among patients with a 
similar body surface area. 
 Our findings raise several important questions. The first is: how can we explain the 
observed differences in toxicity, and what are the roles of genetic and non-genetic factors? 
While the patients’ sex has no effect on the clearance of oxaliplatin [11], sex differences in the 
clearance of 5-FU [12, 13], which are independent of age [14], are likely to explain the 
differences in toxicity observed. As a consequence of their lower clearance of 5-FU, dosing 
according to body surface area results in higher plasma fluoropyrimidine levels in females [12-
14].  
Although the precise reason for the lower clearance of 5-FU in females is not certain, 
the major route of elimination of 5-FU is hepatic metabolism by the enzyme dihydropyrimidine 
dehydrogenase (DPYD). DPYD activity is associated with fluoropyrimidine toxicity [15], but data 
on sex differences in DPYD activity are controversial [16-18]. A strong interaction between 







niversita di Firenze. D
ipartim
ento di farm




predictive impact of several DPD variants in males. By contrast, the lower clearance of 5-FU 
explains the higher toxicity in females. These observations provide a strong case for a sex-
specific approach to personalized fluoropyrimidine dosing. Sex differences in body composition, 
including the higher percentage of metabolically active, fat-free body mass in men [6] may also 
be relevant, because 5-FU pharmacokinetics are better predicted by fat-free mass and total 
body weight than standard anthropometric parameters [21].  
The second major question raised by our analysis is whether the higher plasma levels 
and toxicity in females translate in a higher treatment efficacy. In this context, a recently 
presented, pooled analysis including 18.399 patients in 1st line chemotherapy trials for 
metastatic  colorectal cancer [22] confirmed the higher toxicity, but demonstrated equal 
efficacy of chemotherapy in females and males in terms of both progression-free- and overall 
survival. Thus, differences in pharmacodynamics must be postulated. Whether the tolerability 
of chemotherapies with greater toxicity in female patients could be improved by either dose-
reductions or intensification of supportive care measures only in female patients, and if dose-
reductions  would decrease the efficacy are further important open questions.  
The third major question is whether conventional dosing of 5-FU results in suboptimal 
therapeutic plasma levels in males? The overall lower frequency of toxicities in men could be 
interpreted as a sign of relative under-dosing. Body surface area -based dosing was applied to 
individualizing chemotherapy doses in the 1950s and has remained the default approach, 
although its inaccuracy, including the risk of under-dosing, has been recognized for more than 
15 years [23]. Accordingly, pharmacologists have proposed adjusting doses up or down based 
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with metastatic colorectal cancer, an association between treatment with FOLFOX or 
trifluridine/tiperacil and improved median survival in patients with neutropenia (median 
survival in patients with grade III/IV neutropenia versus without neutropenia for FOLFOX 20.7 
versus 12.5 months, p<.001; for trifluridine/tiperacil 9.8 versus 4.4 months) [25, 26] has been 
reported. A relatively small study of 32 participants confirms that conventional dosing of 5-FU 
results in “sub-therapeutic” plasma levels in the majority of males [13]. In a separate study of 
152 patients, 124 were considered to have “sub-therapeutic” 5-FU levels [27]. To achieve 
“therapeutic” 5-FU levels, the mean 5-FU dose was higher in males (1,837 versus 1,763 
mg/m2/week), respectively [27].   
Arguably, a question of major importance is whether conventional dosing results in 
suboptimal treatment outcomes in males. A close relationship between plasma levels of 5-FU 
and toxicity/efficacy has been observed in patients with several tumor types (for review see 
[28]). A previous analysis of the ACCENT database showed that males had inferior time to 
recurrence (HR 1.05, 95% CI 1.01-1.09) and other efficacy endpoints after adjusting for age, 
stage, and treatment [8]. Interestingly, the stage of disease and type of adjuvant regimen did 
not influence the prognostic value of sex [8]. Another earlier ACCENT database analysis also 
showed that male sex, along with other patient and disease characteristics, was associated with 
increased early (<6 months) mortality [9].  
A key strength of our analysis is the large number of patients included, which allows the 
identification of sex differences with clinical relevance and statistical significance. Furthermore, 
it enables to understand their magnitude while avoiding the risk of errors due to multiple 
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relevant chemotherapy regimens, in which patients do not have confounding factors such as 
prior chemotherapy, which might complicate the interpretation of apparent differences in 
toxicity. Our analysis is, however, limited by the fact that not all types of toxicity were included 
in the ACCENT database. For example, data on neutropenic fever, lethargy, or fatigue are 
absent. Interestingly, a recently published analysis of the phase III PETACC-3 trial of FOLFIRI  
observed all-grade lethargy in 48.9% of females, as compared to 38.2% of males (p< .001)  [29]. 
Furthermore, trials usually report the worst grade of toxicity and not how many times it 
occurred in an individual patient. By necessity, therefore, we focus on differences in incidence 
rather than frequency of a given toxicity; likewise, the durations of these toxicities are also 
unavailable. Finally, data on dose reductions and delays, serious adverse events, and 
hospitalizations due to toxicity, are not captured in the ACCENT database.  
In conclusion, the current analysis raises several important questions, including whether 
males should receive higher doses of 5-FU and whether this may increase the effectiveness of 
adjuvant chemotherapy in males with colon cancer, and whether females should receive either 
reduced doses of 5-FU or different and more intensive supportive treatments. Previous trials 
including pharmacokinetically-adjusted dosing [27, 30] confirmed that the balance between 
efficacy and toxicity of fluoropyrimidines may be improved statistically significantly and 
clinically relevant, but did not change clinical practice. Therefore, further rationally-designed, 
prospective clinical trials investigating alternatives to body surface area-based dosing of 
fluoropyrimidines are required to optimize dosing. Such trials need to take into account the 
well-known sex differences in their effects, as well as other parameters, such as individual body 
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Table 1. Patient Characteristics by Chemotherapy Regimen 
 
Characteristic Female Male Total P-value1 
All patients, No. 15976 18664 34640  
Age, y No. (%)    <.001 
< 50 3022 (18.9) 3142 (16.8) 6164 (17.8)  
50 - 64 7153 (44.8) 8519 (45.6) 15672 (45.2)  
≥ 65 5801 (36.3) 7002 (37.5) 12803 (37.0)  
Missing 0 1 1  
BMI, kg/m2 No. (%)    <.001 
< 18.5  645 (4.5) 208 (1.2) 853 (2.8)  
18.5 - 25  6631 (46.3) 6573 (39.4) 13204 (42.6)  
≥ 25  7056 (49.%) 9889 (59.3) 16945 (54.7)  
Missing 1644 1994 3638  
Performance Score, n (%)    <.001 
0 12224 (78.5) 14675 (80.5) 26899 (79.6)  
1 3233 (20.8) 3383 (18.6) 6616 (19.6)  
2 116 (0.7) 158 (0.9) 274 (0.8)  
3 2 (0.0) 4 (0.0) 6 (0.0)  
Missing 401 444 845  
5FU Patients 10521  12259  22780 
 Age, y No. (%)    <.001 
< 50 1958 (18.6) 1990 (16.2) 3948 (17.3)  
50 - 64 4613 (43.8) 5501 (44.9) 10114 (44.4)  
≥ 65 3950 (37.5) 4768 (38.9) 8718 (38.3)  
BMI, kg/m2 No. (%)    <.001 
< 18.5  412 (4.6) 138 (1.3) 550 (2.9)  
18.5 - 25 4187 (47.1) 4100 (39.9) 8287 (43.2)  
≥ 25 4300 (48.3) 6043 (58.8) 10343 (53.9)  
Missing 1622 1978 3600  
Performance Score, No. (%)    <.001 
0 7851 (77.2) 9408 (79.4) 17259 (78.4)  
1 2203 (21.7) 2292 (19.3) 4495 (20.4)  
2 109 (1.1) 149 (1.3) 258 (1.2)  
3 1 (0.0) 4 (0.0) 5 (0.0)  
Missing 357 406 763  
FOLFOX Patients 2720 3149 5869 
 Age, y No. (%)    .08 
< 50 573 (21.1) 608 (19.3) 1181 (20.1)  
50 - 64 1315 (48.3) 1502 (47.7) 2817 (48.0)  
≥ 65 832 (30.6) 1039 (33.0) 1871 (31.9)  
BMI, kg/m2 No. (%)    <.001 
< 18.5  106 (3.9) 20 (0.6) 126 (2.1)  
18.5 - 25 1183 (43.5) 1134 (36.0) 2317 (39.5)  
≥ 25 1430 (52.6) 1995 (63.4) 3425 (58.4)  
Missing 1 0 1  
Performance Score, No. (%)    .53 
0 2247 (83.2) 2621 (83.9) 4868 (83.6)  
1 449 (16.6) 495 (15.9) 944 (16.2)  
2 4 (0.1) 7 (0.2) 11 (0.2)  
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Missing 19 26 45  
Capecitabine Patients 888 1026 1914 
 Age, y, No. (%)    .17 
< 50 121 (13.6) 141 (13.8) 262 (13.7)  
50 - 64 387 (43.6) 487 (47.5) 874 (45.7)  
≥ 65 380 (42.8) 397 (38.7) 777 (40.6)  
Missing 0 1 1  
     
BMI, kg/m2  No.(%)    <.001 
< 18.5  42 (4.8) 13 (1.3) 55 (2.9)  
18.5 - 25  434 (49.2) 449 (44.2) 883 (46.5)  
≥ 25  406 (46.0) 554 (54.5) 960 (50.6)  
Missing 6 10 16  
Performance Score, No. (%)    .84 
0 750 (84.8) 867 (84.5) 1617 (84.7)  
1 134 (15.2) 159 (15.5) 293 (15.3)  
Missing 4 0 4  
CAPOX Patients 850 1014 1864 
 Age, y No. (%)    .10 
< 50 146 (17.2) 176 (17.4) 322 (17.3)  
50 - 64 361 (42.5) 475 (46.8) 836 (44.8)  
≥ 65 343 (40.4) 363 (35.8) 706 (37.9)  
BMI, kg/m2  No. (%)    <.001 
< 18.5  43 (5.1) 20 (2.0) 63 (3.4)  
18.5 - 25  376 (44.2) 415 (40.9) 791 (42.4)  
≥ 25  431 (50.7) 579 (57.1) 1010 (54.2)  
Performance Score, No. (%)    .03 
0 607 (72.3) 774 (76.8) 1381 (74.7)  
1 233 (27.7) 234 (23.2) 467 (25.3)  
Missing 10 6 16  
FOLFIRI Patients 997 1216 2213 
 Age, y No. (%)    .005 
< 50 224 (22.5) 227 (18.7) 451 (20.4)  
50 - 64 477 (47.8) 554 (45.6) 1031 (46.6)  
≥ 65 296 (29.7) 435 (35.8) 731 (33.0)  
BMI, kg/m2  No. (%)    <.001 
< 18.5  42 (4.3) 17 (1.4) 59 (2.7)  
18.5 - 25  451 (45.9) 475 (39.3) 926 (42.2)  
≥ 25  489 (49.8) 718 (59.3) 1207 (55.1)  
Missing 15 6 21  
Performance Score, No. (%)    .01 
0 769 (78.0) 1005 (83.1) 1774 (80.8)  
1 214 (21.7) 203 (16.8) 417 (19.0)  
2 3 (0.3) 2 (0.2) 5 (0.2)  
Missing 11 6 17  
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Figure Titles and Legends 
Figure 1. Adjusted Odds Ratios (95% confidence intervals) for grade III/IV hematological 
toxicities (log base 10 scale).  *Stratified by study and treatment arm,  adjusted for age, stage 
grade, PS, and BMI;  **Stratified Wald p-value; 5FU=Fluorouracil therapy, FOLFOX=Leucovorin + 
Fluorouracil + Oxaliplatin therapy, CAPOX=Capecitabine + Oxaliplatin therapy, CI=Confidence 
Interval, PS=Performance Status, BMI=Body Mass Index 
Figure 2. Adjusted Odds ratios (95% confidence intervals) for grade III/IV non-hematological 
toxicities (log base 10 scale). *Stratified by study and treatment arm,  adjusted for age, stage 
grade, PS, and BMI;  **Stratified Wald p-value; 5FU=Fluorouracil therapy, FOLFOX=Leucovorin + 
Fluorouracil + Oxaliplatin therapy, CAPOX=Capecitabine + Oxaliplatin therapy, CI=Confidence 
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